Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Company Profile and bullboard matches:

TXMD , T.HLS , T.CTX , T.GUD , V.XRTX , T.CRDL , T.APLI
Sort by: Date|Relevance

A New Frontier in Psychedelic Therapeutics

Cybin X Kernel "A New Frontier in Psychedelic Therapeutics" About the partnership: Cybin Corporation ( N.CYBN , Forum ) will leverage Kernel’s Flow to quantify brain activity during psychedelic experiences in re...
Featured Submission | January 11, 2021 |

Developer of Oncology Therapeutics to Have 'Catalyst Rich' 2020

The near-term events expected to trigger movement of the biotech's share price are outlined in a ROTH Capital Partners report. In a Jan. 2 research note, ROTH Capital Partners analyst Jonathan Aschoff reported that he is assuming coverage on VBL Therapeutics (VBLT:NA...
Streetwise Reports | January 9, 2020 |

Leap Therapeutics Lunges Forward on $132M Licensing Deal and $27M Equity Raise

Shares of Leap Therapeutics jumped 60% after the company reported that it signed an exclusive option and license agreement for its immuno-oncology drug DKN-01 with BeiGene in the Asia Pacific region excluding Japan. The firm also secured an additional $27 million in equity fin...
Streetwise Reports | January 6, 2020 |

A Potential Psychedelic and COVID Therapy Play…All in One Stock

The global concern over the ongoing coronavirus pandemic isn’t going away and even the White House’s health advisor is concerned about what protection a potential vaccine may deliver…but…could there be an answer in a drug that already exists?...
Dave Jackson | June 16, 2020 |

Akcea Therapeutics Inks Worldwide Licensing Deal with Pfizer...

Akcea Therapeutics Inks Worldwide Licensing Deal with Pfizer for Investigative Antisense Therapy, Shares Up 30% Akcea Therapeutics' shares are trading 30% higher today on news that it has entered into a worldwide exclusive licensing agreement with Pfizer for AKCEA-ANG...
Streetwise Reports | October 8, 2019 |

Applied Therapeutics Investors Like the ACTION in Phase 2 Galactosemia Study

Applied Therapeutics' shares traded 25% higher today after the company reported positive topline results from its Pivotal Phase 2 ACTION Study of AT-007 for use in the treatment of galactosemia. The firm expects to file for regulatory approval of AT-007 in H2/20. This...
Streetwise Reports | January 9, 2020 |

Iterum Therapeutics Shares Double After Completing Enrollment in Phase 3 Antibiotic Trial

Iterum Therapeutics shares traded more than 100% higher after the company reported that it has completed enrollment in its Phase 3 SURE 1 clinical study of oral sulopenem for treatment of uncomplicated urinary tract infections. The firm expects to receive topline data results ...
Streetwise Reports | December 30, 2019 |

FDA Accepts NDA for Global Blood Therapeutics' Sickle Cell Drug; Shares Up 14%

Shares of Global Blood Therapeutics are trading more than 14% higher after the FDA accepted its New Drug Application filing for Voxelotor, a drug used in the treatment of sickle cell disease. Earlier today clinical-stage biopharmaceutical firm Global Blood Therapeuti...
Streetwise Reports | September 6, 2019 |

Neon Therapeutics Shares Are Flashing Brightly after Reporting Predictive Cancer Breakthrough

After announcing publication in the scientific journal Immunity that it had created a 61-fold improvement process for predicting cancer-specific antigens, Neon Therapeutics' stock has traded wildly today, up more than 46% at times on nearly 100-times average daily volume, bu...
Streetwise Reports | September 9, 2019 |

Plus Therapeutics Shares Trade Higher on Q3 Earnings and Business Restructuring

Plus Therapeutics shares opened 25% higher today after the firm reported Q3/19 financial and business results. In the most recent quarter, the company completed the change of its name, relocated its headquarters to Austin, and raised $15 million for R&D and working capital. ...
Streetwise Reports | November 18, 2019 |
1 2 3 4 5 6 7 8 9 10 ...